Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

NCT04051112 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Ascites

Interventions

DRUG: SCB-313

Sponsor

Sichuan Clover Biopharmaceuticals, Inc.